Pfizer Venture Investments — 2017 Investments

3 investments dated 2017 · listed companies and verified rows first · show all

Rhythm Pharmaceuticalsrhythmtx.com in 𝕏Jan 2017

Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway.

BiotechDigital HealthHealthtechMedical DevicesBoston, US

Keith Gottesdiener(Executive Officer, Director)inBart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)inDavid Meeker(President and Chief Executive Officer)in

BoardEdward T. Mathers(Director)inJonathan Silverstein(Director)inNeil Exter(Director)in

Co-investorsForesite Capital HEALTHCARE ROYALTY PARTNERS New Enterprise Associates (NEA)Wellington Management OrbiMed Third Rock Ventures

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Complexa Cydan II

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.